Molecular symmetry and biological activities of new symmetrical tris(2-aminoethyl)amine derivatives

Chemical and Pharmaceutical Bulletin

Volumn 60, Issue 3, 2012, Pages 408-414

  Mibu, Nobuko ^a   Yokomizo, Kazumi ^b   Uchida, Wataru ^a   Takemura, Satoshi ^a   Zhou, Jianrong ^b   Aki, Hatsumi ^a   Miyata, Takeshi ^b   Sumoto, Kunihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

Author keywords

Anti herpes simplex virus type 1; C 3 symmetry; C S symmetry; Plaque reduction assay; Tripodal; Tris(2 aminoethyl)amine

Indexed keywords

ANTIVIRUS AGENT; MOLECULAR SCAFFOLD; TRIS(2 AMINOETHYL)AMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; NONHUMAN; VERO CELL;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; ETHYLENEDIAMINES; HERPESVIRUS 1, HUMAN; VERO CELLS; VIRAL PLAQUE ASSAY;

EID: 84863246382     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.60.408     Document Type: Article

References (29)

1. Oshovsky G. V., Reinhoudt D. N., Verboom W., Angew. Chem. Int. Ed., 46, 2366-2393 (2007).
2. Bostina M., Levy H., Filman D. J., Hogle J. M., J. Virol., 85, 776-783 (2011).
3. Li L., Jose J., Xiang Y., Kuhn R. J., Rossmann M. G., Nature (London), 468, 705-708 (2010).
4. Balzarini J., Antiviral Res., 71, 237-247 (2006).
5. Contreras J.-M., Sippl W., "The Practice of Medicinal Chemistry,"3rd ed., ed. by Wermuth C. G., Elsevier Academic Press, London, 2008, pp. 380-414.
6. Gibson S. E., Castaldi M. P., Angew. Chem. Int. Ed., 45, 4718-4720 (2006).
7. Humblet V., Misra P., Bhushan K. R., Nasr K., Ko Y.-S., Tsukamoto T., Pannier N., Frangioni J. V., Maison W., J. Med. Chem., 52, 544-550 (2009).
8. Mibu N., Yokomizo K., Uyeda M., Sumoto K., Chem. Pharm. Bull., 53, 1171-1174 (2005).
9. Mibu N., Yokomizo K., Miyata T., Sumoto K., J. Heterocyclic Chem., 47, 1434-1438 (2010) and references are cited therein.
10. 3-symmetrical molecule having a tripodal scaffold may be an efficient structural feature for molecular recognition such as recognition of sugar chains in macromolecules or receptor sites. The rigidity of the molecules and nature of functional groups (such as H-bond donors or acceptors for suprafacial interactions) in symmetrical target molecules may play important roles for its biological properties.
11. Abe H., Aoyagi Y., Inouye M., Org. Lett., 7, 59-61 (2005).
12. Mazik M., Sonnenberg C., J. Org. Chem., 75, 6416-6423 (2010).
13. Kim H.-J., Kim Y.-H., Hong J.-I., Tetrahedron Lett., 42, 5049-5052 (2001).
14. Kim J., Kim S.-G., Seong H. R., Ahn K. H., J. Org. Chem., 70, 7227-7231 (2005).
15. Boon J. M., Lambert T. N., Smith B. D., Beatty A. M., Ugrinova V., Brown S. N., J. Org. Chem., 67, 2168-2174 (2002) and related references cited therein.
16. Berezin S. K., Davis J. T., J. Am. Chem. Soc., 131, 2458-2459 (2009).
17. Ma C. M., Nakamura N., Hattori M., Chem. Pharm. Bull., 49, 915-917 (2001).
18. Valiyaveettil S., Engbersen J. F. J., Verboom W., Reinhoudt D. N., Angew. Chem. Int. Ed. Engl., 32, 900-901 (1993).
19. Tapper S., Littlechild J. A., Molard Y., Prokes I., Tucker J. H. R., Supramol. Chem., 18, 55-58 (2006).
20. Schinazi R. F., Peters J., Williams C. C., Chance D., Nahmias A., Antimicrob. Agents Chemother., 22, 499-507 (1982).
21. Ikeda T., Yokomizo K., Okawa M., Tsuchihashi R., Kinjo J., Nohara T., Uyeda M., Biol. Pharm. Bull., 28, 1779-1781 (2005).
22. -1 in aqueous 25% 2-propanol solution at 25°C. The results of sugar recognition of the products will be described elsewhere in detail.
23. Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J., Adv. Drug Deliv. Rev., 23, 3-25 (1997).
24. Hansch C., Kim D., Leo A. J., Novellino E., Silipo C., Vittoria A., Bond J. A., Henderson R. F., Crit. Rev. Toxicol., 19, 185-226 (1989).
25. Log P were calculated by using CAChe (v.6.1.12).
26. We have already observed that some of the compounds with high levels of cytotoxicity against Vero cells also show an interesting antitumor activity. Therefore, this assay for cytotoxicity of compounds may provide a conventional pre-screening procedure for such compounds. 27,28)
27. Thongthoom T., Promsuwan P., Yenjai C., Eur. J. Med. Chem., 46, 3755-3761 (2011).
28. Sen S., Sarker K., Ghosh A., Mishra S., Saha A., Goswami D., Jha T., Gupta J. K., De A. U., Int. J. Pharm. Sci. Rev. Res., 10, 118-124 (2011).
29. Mibu N., Yokomizo K., Kashige N., Miake F., Miyata T., Uyeda M., Sumoto K., Chem. Pharm. Bull., 55, 111-114 (2007).